Company
Actinogen Medical Ltd
ASX:ACW
Actinogen Medical is a biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. The company is currently developing its lead compound, Xanamem®, as a revolutionary new therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact.
37 stories
Actinogen Medical opens SPP after successful $15 million placement
Funding will go towards the company's lead drug candidate Xanamem™.
Actinogen Medical attracts $15 million to progress Alzheimer’s disease therapy
The company's shares are trading about 9% higher intra-day, at 4.9 cents.
Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial
The annual cost of managing Alzheimer’s disease is estimated to be US$250B in the U.S.
Actinogen Medical begins landmark Alzheimer’s disease clinical trial
The largest Alzheimer’s study ever conducted by an Australian company.
Actinogen Medical on track to begin Alzheimer’s disease trial
The company has received approval for the trial in the UK.
Actinogen Medical in an ASX trading halt
Actinogen Medical (ASX:ACW) has been granted a trading halt by the ASX, with its shares placed in pre-open.